London-based digital health company MedPal AI, which combines AI-driven wellness technology with automated pharmacy services, has reported strong month-on-month growth alongside a major regulatory milestone in the weight management market.

During December 2025, the MedTech processed 33,433 prescriptions, a 16% increase on November’s 28,789, despite the shortened Christmas trading period.

The growth was supported by the continued rollout of its NHS distance selling pharmacy contract and rising demand for its private weight loss service, delivered through its AI-enabled pharmacy operation.

The update follows FDA approval of Novo Nordisk’s Wegovy pill, the first oral GLP-1 treatment for weight loss, which the business believes could further accelerate uptake across its AI-powered health and prescription platforms.

Its share price is up 6.67% today to 5.33p.